JP2005314368A - Gold ion-containing liquid medicine for preventing/treating cancer - Google Patents
Gold ion-containing liquid medicine for preventing/treating cancer Download PDFInfo
- Publication number
- JP2005314368A JP2005314368A JP2005067639A JP2005067639A JP2005314368A JP 2005314368 A JP2005314368 A JP 2005314368A JP 2005067639 A JP2005067639 A JP 2005067639A JP 2005067639 A JP2005067639 A JP 2005067639A JP 2005314368 A JP2005314368 A JP 2005314368A
- Authority
- JP
- Japan
- Prior art keywords
- gold
- liquid medicine
- cancer
- ppm
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000010931 gold Substances 0.000 title claims abstract description 75
- 229910052737 gold Inorganic materials 0.000 title claims abstract description 75
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 59
- 201000011510 cancer Diseases 0.000 title claims abstract description 39
- 239000007788 liquid Substances 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title abstract description 14
- -1 gold ion Chemical class 0.000 claims abstract description 55
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 238000011580 nude mouse model Methods 0.000 abstract description 14
- 241000699670 Mus sp. Species 0.000 abstract description 10
- 241000699660 Mus musculus Species 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 230000001093 anti-cancer Effects 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 6
- 238000002054 transplantation Methods 0.000 abstract description 6
- 239000003651 drinking water Substances 0.000 abstract description 2
- 235000020188 drinking water Nutrition 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 13
- 206010006187 Breast cancer Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- QZPSXPBJTPJTSZ-UHFFFAOYSA-N aqua regia Chemical compound Cl.O[N+]([O-])=O QZPSXPBJTPJTSZ-UHFFFAOYSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 239000003973 paint Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 241000282465 Canis Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 150000003841 chloride salts Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910001902 chlorine oxide Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- KFZAUHNPPZCSCR-UHFFFAOYSA-N iron zinc Chemical compound [Fe].[Zn] KFZAUHNPPZCSCR-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、がんの予防および治療に有効な金イオン含有液剤および金イオンを有効成分として含有する抗がん剤に関するものである。 The present invention relates to a gold ion-containing liquid agent effective for cancer prevention and treatment and an anticancer agent containing gold ion as an active ingredient.
古くから金は、各種疾病や菌に対して効能があるとして、飲食物、塗り薬、化粧料等の中に配合されたりしている。しかし、従来の金入りの飲食物、塗り薬、化粧料の場合、金は金箔、金粉の状態で液剤中あるいは乳剤等に配合されているため、その人体への吸収性が不十分であり、金の効能が十分に発揮されていないのが現状である。 Since ancient times, gold has been incorporated into foods and drinks, paints, cosmetics and the like as having an effect on various diseases and bacteria. However, in the case of conventional foods and drinks containing gold, paints, and cosmetics, gold is blended in liquids or emulsions in the form of gold foil or gold powder, so its absorption into the human body is insufficient, and gold The present condition is that the effect of is not fully demonstrated.
また、西洋医学分野では、慢性関節リウマチの治療に際し、金を含む水溶性の有機化合物を注射薬の形で注射することが既に行われている。しかし、上記の有機化合物の場合、金が有機化合物との錯体を形成することによって水溶化が図られているので、分子が大きく、金の性能が十分に発揮されているとはいえない。また、有機物を含むため副作用の問題があった。 In the field of Western medicine, in the treatment of rheumatoid arthritis, water-soluble organic compounds containing gold have already been injected in the form of injections. However, in the case of the above-described organic compound, since water is solubilized by forming a complex with the organic compound, it cannot be said that the molecule is large and gold performance is sufficiently exhibited. Moreover, since it contains organic substances, there was a problem of side effects.
そこでこのような問題を解決すべく、下記特許文献１には、経口投与または塗布により人体への吸収性にすぐれ、金の優れた効能を発揮することができ、その上、副作用の少ない金イオン含有液剤と、その効率のよい製造方法とが開示されている。そして、この金イオン含有液剤を飲用すると、例えば、リウマチ、高血圧症、心臓病、婦人病、皮膚炎、喘息、発毛、皮膚の美化、健康増進等に効果を発揮することが記載されている。 Therefore, in order to solve such a problem, the following Patent Document 1 discloses gold ion which is excellent in absorbability to the human body by oral administration or application, can exhibit excellent effects of gold, and has few side effects. A liquid containing agent and its efficient production method are disclosed. And, it is described that when this gold ion-containing liquid is taken, it exhibits effects on, for example, rheumatism, hypertension, heart disease, gynecological disease, dermatitis, asthma, hair growth, skin beautification, health promotion, etc. .
また、下記非特許文献１には、この金イオン含有液剤を製品化した「純金イオン水」を実際に飲水した場合の症例報告が記載されている。具体的には、この「純金イオン水」を飲用することによって、動脈硬化症、婦人病、腎臓病、糖尿病性網膜症、皮膚炎、糖尿病性腎不全、視力障害、足指壊疽、心臓病、高血圧症、全身がん、関節リウマチ、喘息などの各疾患に症状緩和がみられ、あるいは病気が完治した旨、各患者の体験が綴られている。 Non-Patent Document 1 below describes a case report when “pure gold ion water” obtained by commercializing this gold ion-containing liquid is actually drunk. Specifically, by drinking this "pure gold ion water", arteriosclerosis, gynecological disease, kidney disease, diabetic retinopathy, dermatitis, diabetic renal failure, visual impairment, toe gangrene, heart disease, Each patient's experience is spelled out that symptoms such as hypertension, systemic cancer, rheumatoid arthritis, and asthma have been alleviated or the disease has been completely cured.
上記のように、金イオン含有液剤は、育毛作用、美白作用といった美容効果のみならず、様々な疾患に対して改善効果を有することが患者の体験から認められるが、患者個人の体験ゆえに不確実であり、今後はこれら諸効果を科学的に裏付け、得られた実験データに基づき各疾患に適した用法、用量等を見出すことが重要になってくる。このような観点から、本発明者は、特にがんの予防・治療効果に着目し、金イオン含有液剤が実際にがん予防・治療効果を有しているかどうかを実験により確かめることにした。 As described above, it is recognized from the experience of patients that gold ion-containing liquid preparations have not only cosmetic effects such as hair-growth and whitening effects, but also various diseases. In the future, it will be important to scientifically support these various effects and to find the appropriate usage, dosage, etc. for each disease based on the experimental data obtained. From this point of view, the present inventor has paid particular attention to cancer prevention / treatment effects and decided to confirm whether or not the gold ion-containing liquid agent actually has cancer prevention / treatment effects by experiments.
本発明は、このように、金イオン含有液剤のがん予防・治療効果の有無を検討することによって、がんの予防および治療に有効な金イオン含有液剤、および、金イオンを有効成分として含有する抗がん剤を提供することをその課題とするものである。 Thus, the present invention examines the presence or absence of cancer prevention / treatment effects of gold ion-containing liquids, thereby containing gold ion-containing liquids effective for cancer prevention and treatment, and gold ions as active ingredients. Therefore, it is an object of the present invention to provide an anticancer agent to be used.
本発明者は、上記の課題に鑑み鋭意研究を進めた結果、癌細胞を皮下移植した実験動物に対して金イオン水を投与した場合と投与しなかった場合とで、一定期間経過後の腫瘍体積を比較したところ、金イオン水を投与した場合には腫瘍体積が有意に小さくなり、金イオン水に抗腫瘍活性が認められること、また、金イオン水の抗腫瘍効果は、金イオン濃度が高いほど強く認められること、等を見出し、本発明を完成するに至った。 As a result of advancing earnest research in view of the above problems, the present inventor has found that tumors after a certain period of time have passed between when the gold ion water is administered to experimental animals transplanted with cancer cells subcutaneously and when they are not administered. When the volume was compared, when gold ion water was administered, the tumor volume was significantly reduced, and anti-tumor activity was observed in gold ion water. It was found that the higher the value, the stronger it was recognized, and the present invention was completed.
即ち、本発明は、金イオンを有効成分として含有する、がんの予防又は治療用液剤である。このがん予防・治療用液剤は、少なくとも金無機塩が溶解している構成であればよく、亜鉛イオン等を含んでいてもよい。金イオンは、１ｐｐｍ以上４０ｐｐｍ以下の割合で含有されていることが好ましい。即ち、１ｐｐｍ未満では、金の効能を十分に発揮できない場合がある。他方、金イオン濃度があまり高濃度であると、体内への金の蓄積による弊害を起こす恐れがあるので、経口使用時の金イオン濃度は４０ｐｐｍ以下（より好ましくは２ｐｐｍ〜８ｐｐｍ）が好ましい。 That is, the present invention is a liquid for cancer prevention or treatment containing gold ions as an active ingredient. The solution for cancer prevention / treatment only needs to have a structure in which at least a gold inorganic salt is dissolved, and may contain zinc ions or the like. It is preferable that gold ions are contained at a ratio of 1 ppm or more and 40 ppm or less. That is, if it is less than 1 ppm, the effect of gold may not be fully exhibited. On the other hand, if the gold ion concentration is too high, the gold ion concentration in the body may cause adverse effects, so the gold ion concentration during oral use is preferably 40 ppm or less (more preferably 2 ppm to 8 ppm).
また、本発明は、金イオンの抗がん作用に着目し完成されたものであり、金イオンを有効成分として含有する抗がん剤も本発明に含まれる。抗がん剤は、液剤に限られず、金イオンを有効成分として含有するものであれば、剤形は特に限定されるものではなく、錠剤、カプセル剤、散剤、顆粒剤、シロップ剤、注射剤、軟膏剤、坐剤などとして投与することができる。 The present invention has been completed by paying attention to the anticancer action of gold ions, and anticancer agents containing gold ions as an active ingredient are also included in the present invention. The anticancer agent is not limited to a liquid agent, and the dosage form is not particularly limited as long as it contains gold ions as an active ingredient. Tablets, capsules, powders, granules, syrups, injections , Ointments, suppositories, and the like.
本発明のがん予防・治療用液剤の使用法も特に限定されるものではなく、飲料、食品、嗜好品、経口薬中に入れるなどして口から体内に供給してもよいし、化粧品や塗り薬中に配合し、皮膚から体内に吸収させたりすることができる。なお、飲料として使用する場合には水溶液の状態とすることが好ましいが、ゲル状等でも構わない。また、化粧品や塗り薬等として使用する場合は、エマルジョン化した乳液状としても構わない。さらに、本発明のがん予防・治療用液剤中には、必要に応じて、公知の健康食品や健康飲料に使用されているビタミン類、甘味料等の各種添加物を添加することができる。 The method of using the liquid for cancer prevention / treatment of the present invention is not particularly limited, and it may be supplied into the body through the mouth by putting it in a drink, food, luxury product, oral medicine, cosmetics, It can be blended into the paint and absorbed into the body through the skin. In addition, although it is preferable to set it as the state of aqueous solution when using as a drink, a gel form etc. may be sufficient. Moreover, when using as cosmetics, a coating agent, etc., it does not matter as an emulsion emulsion. Furthermore, various additives such as vitamins and sweeteners used in known health foods and health drinks can be added to the cancer prevention / treatment liquid of the present invention as necessary.
本発明のがん予防・治療用液剤および抗がん剤は、上述のように、金イオンを有効成分として含有し、抗がん作用を有することから、医薬品および飲食品（特に健康飲料水）、さらには化粧品等への利用が可能である。 Since the cancer preventive / therapeutic solution and anticancer agent of the present invention contain gold ions as an active ingredient and have an anticancer effect as described above, they are pharmaceuticals and foods and drinks (especially health drinks). Furthermore, it can be used for cosmetics and the like.
具体的な使用法としては、例えば、本発明のがん予防・治療用液剤を飲料水または食事に混ぜ服用する。対象はヒトだけではなく、犬猫などの伴侶動物であっても勿論よい。本発明の抗がん剤は、正常ヒト（動物）に対しては癌予防剤として、他方、癌患者には癌増殖抑制剤として適応できる。癌患者には、他の抗がん剤との併用も可能であり、エックス線治療との併用も可能である。また、皮膚癌などの表在性腫瘍には軟膏や湿布薬として投与してもよい。 As a specific usage, for example, the liquid for cancer prevention / treatment of the present invention is mixed with drinking water or a meal and taken. Of course, the subject may be not only a human but also a companion animal such as a dog or cat. The anticancer agent of the present invention can be used as a cancer preventive agent for normal humans (animals) and as a cancer growth inhibitory agent for cancer patients. Cancer patients can be used in combination with other anticancer agents, and can also be used in combination with X-ray therapy. In addition, superficial tumors such as skin cancer may be administered as an ointment or poultice.
以下、本発明の実施の一形態について説明する。
本発明のがん予防・治療用液剤は、特開２００３−１０４８９８号公報に記載の方法によって製造可能である。具体的には、まず金（金箔など）を王水（塩酸３：硝酸１）で溶解した金溶液と、亜鉛および鉄を塩酸で溶解した亜鉛−鉄溶液とを混合し、この混合溶液を坩堝や蒸発皿などの耐高熱容器に入れた状態で、耐高熱容器を加熱して、混合溶液を耐高熱容器内で蒸発乾固する。
Hereinafter, an embodiment of the present invention will be described.
The liquid for cancer prevention / treatment of the present invention can be produced by the method described in JP-A No. 2003-104898. Specifically, first, a gold solution in which gold (gold leaf or the like) is dissolved in aqua regia (hydrochloric acid 3: nitric acid 1) and a zinc-iron solution in which zinc and iron are dissolved in hydrochloric acid are mixed. In a high heat resistant container such as an evaporating dish, the high heat resistant container is heated, and the mixed solution is evaporated to dryness in the high heat resistant container.
次に、この蒸発乾固物に、１０００℃以上の炎に直接当てて、蒸発乾固物中の不要な塩素や窒素酸化物を分解し、金、亜鉛、鉄の水溶性塩化物塩を得る。そして、この水溶性塩化物塩を精製水で溶かして本発明の金イオン含有がん予防・治療用液剤を得る。この製造方法によれば、酸性原料溶液中に塩化亜鉛が混合されているので、金イオンの収率が向上する。 Next, this evaporated and dried product is directly exposed to a flame of 1000 ° C. or more to decompose unnecessary chlorine and nitrogen oxides in the evaporated and dried product to obtain water-soluble chloride salts of gold, zinc and iron. . Then, the water-soluble chloride salt is dissolved with purified water to obtain the gold ion-containing cancer prevention / treatment liquid of the present invention. According to this production method, since zinc chloride is mixed in the acidic raw material solution, the yield of gold ions is improved.
上記製造方法以外の方法で本発明のがん予防・治療用液剤を製造しても勿論よい。例えば、上記製造方法では、まず金箔を王水で溶かした溶液と、亜鉛および鉄を塩酸で溶かした溶液とを混合することによって、酸性原料溶液を得るようにしているが、金箔、亜鉛、鉄を王水で同時に溶解させても構わない。また、金箔を王水で溶かした溶液に塩化亜鉛や塩化第２鉄などを混合するようにしても構わない。また、上記製造方法では、蒸発乾固物に対して直接炎を当てるようにしているが、坩堝越しに強熱するようにしても構わない。 Of course, the liquid for cancer prevention / treatment of the present invention may be produced by a method other than the above production method. For example, in the above production method, an acidic raw material solution is first obtained by mixing a solution obtained by dissolving gold foil with aqua regia and a solution obtained by dissolving zinc and iron with hydrochloric acid. May be dissolved simultaneously with aqua regia. Further, zinc chloride or ferric chloride may be mixed in a solution obtained by dissolving a gold foil with aqua regia. Further, in the above manufacturing method, the flame is directly applied to the evaporated and dried product, but it may be ignited through the crucible.
このようにして製造された本発明のがん予防・治療用液剤を癌細胞を皮下移植したヌードマウスに経口投与し、腫瘍体積を非投与群と比較したところ、本液剤投与群では腫瘍体積が有意に小さくなり、本液剤にはin vivo抗腫瘍活性が認められた（図２および図３参照）。なお、これら実験の詳細については、後述の実施例で説明する。 The liquid for cancer prevention / treatment of the present invention produced in this way was orally administered to nude mice transplanted subcutaneously with cancer cells, and the tumor volume was compared with the non-administration group. The solution was significantly reduced, and in vivo antitumor activity was observed with this solution (see FIGS. 2 and 3). The details of these experiments will be described in the examples described later.
このように本発明のがん予防・治療用液剤は、抗がん作用を有することから、例えば抗がん作用又はがん予防効果をもつ健康飲料水として利用できる。 Thus, since the liquid for cancer prevention / treatment of the present invention has an anticancer action, it can be used, for example, as a health drink having an anticancer action or a cancer prevention effect.
また、前述のように、本発明は、金イオンを有効成分として含有する抗がん剤であってもよい。対象となる癌の種類は特に限定されるものではないが、実際に乳癌に対する増殖抑制効果が認められたので、乳癌に対する効果的な抗がん剤としての利用が期待できる。 Moreover, as mentioned above, the present invention may be an anticancer agent containing gold ions as an active ingredient. Although the kind of cancer used as object is not specifically limited, Since the growth inhibitory effect with respect to a breast cancer was actually recognized, the utilization as an effective anticancer agent with respect to a breast cancer can be anticipated.
本発明の抗がん剤についても、上記と同様の製造方法によって製造することができ、各剤形への製造も公知の方法にしたがって行えばよい。 The anticancer agent of the present invention can also be produced by the same production method as described above, and the production into each dosage form may be performed according to a known method.
以下、図面を参照しながら本発明の実施例について説明するが、本発明は下記実施例によって何ら限定されるものではない。 Hereinafter, examples of the present invention will be described with reference to the drawings, but the present invention is not limited to the following examples.
［実施例１］
本実施例においては、癌細胞を皮下移植した実験動物に対して本発明の金イオン含有液剤を自由飲水させ、所定期間経過後に腫瘍体積を測定し、対照動物と比較することによって、本発明の金イオン含有液剤の抗腫瘍活性を評価した。
[Example 1]
In this example, the experimental animal transplanted subcutaneously with cancer cells was allowed to freely drink the gold ion-containing solution of the present invention, the tumor volume was measured after a predetermined period of time, and compared with a control animal. The antitumor activity of the gold ion-containing solution was evaluated.
実験動物には、８週齢雌ヌードマウスBALB/cを使用した。このヌードマウスは、先天的に胸腺が欠如し、免疫不全のため、癌細胞を皮下移植すると腫瘍が形成され、経時的に肥大化する。 As experimental animals, 8-week-old female nude mice BALB / c were used. This nude mouse has a congenital lack of thymus, and because of immunodeficiency, when a cancer cell is transplanted subcutaneously, a tumor is formed and becomes enlarged over time.
本実施例において移植に使用した癌細胞は、マウス由来乳癌細胞株Jyg B-cellである（Hiroishi et al., Cancer Letters (1995), 92, 83-86頁：Tsukamoto et al., Internati
onal Journal of Oncology (2003), 23, 1671-1677頁参照）。この細胞株はヌードマウス
に移植することにより、癌転移実験のモデルとして用いられている。
The cancer cell used for transplantation in this example is a mouse-derived breast cancer cell line Jyg B-cell (Hiroishi et al., Cancer Letters (1995), 92, 83-86: Tsukamoto et al., Internati
onal Journal of Oncology (2003), 23, 1671-1677). This cell line has been used as a model for cancer metastasis experiments by transplanting into nude mice.
本発明の金イオン含有液剤としては、前述の方法で製造した金イオン水（商品名「純金イオン水」。金イオン濃度は２ｐｐｍおよび５ｐｐｍの２種類）を使用した。対照ヌードマウスには、金イオンを含まない（即ち、金イオン濃度０ｐｐｍの）水を与えた。 As the gold ion-containing liquid agent of the present invention, gold ion water (trade name “pure gold ion water” manufactured by the above-described method. Two kinds of gold ion concentrations of 2 ppm and 5 ppm) were used. Control nude mice were given water without gold ions (ie gold ion concentration 0 ppm).
実験では、まず、金イオン濃度０ｐｐｍ、２ｐｐｍ、５ｐｐｍの水をそれぞれ５匹のヌードマウスに自由飲水させた。１週間後、各ヌードマウスに対してJyg B-cell（1.4×106個）を頚部皮下に移植した。その後も純金イオン水（対照マウスには金イオンを含まない水）を自由飲水させ、移植３週間目にマウスを安楽死し、各マウスの腫瘍体積を測定した。そして、金イオン濃度０ｐｐｍ、２ｐｐｍ、５ｐｐｍの水を投与したマウス群ごとに平均値を算出し、Student-tにより０ｐｐｍ投与との有意差検定を行った。 In the experiment, first, five nude mice were allowed to freely drink water with gold ion concentrations of 0 ppm, 2 ppm, and 5 ppm, respectively. One week later, each nude mouse was transplanted with Jyg B-cell (1.4 × 10 6 cells) subcutaneously in the neck. Thereafter, pure gold ionized water (water that does not contain gold ions in control mice) was allowed to drink freely, the mice were euthanized 3 weeks after transplantation, and the tumor volume of each mouse was measured. Then, an average value was calculated for each group of mice administered with gold ion concentrations of 0 ppm, 2 ppm, and 5 ppm, and a significant difference test with 0 ppm was performed by Student-t.
上記実験結果が、図１および図２に示される。図１は、Jyg B-cell皮下移植３週目の担腫瘍マウスの肉眼所見を示す図である。同図に示すように、純金イオン水（２ｐｐｍおよび５ｐｐｍ）を投与したマウスでは、コントロール（０ｐｐｍ）と比較して腫瘍（図中、矢印）が小さく、換言すれば、腫瘍の肥大化が顕著に抑制された。また、純金イオン水の濃度が高いほど（つまり、２ｐｐｍ投与群よりも５ｐｐｍ投与群のほうが）腫瘍は小さかった。 The experimental results are shown in FIG. 1 and FIG. FIG. 1 is a graph showing macroscopic findings of tumor-bearing mice at 3 weeks after subcutaneous implantation of Jyg B-cell. As shown in the figure, in the mice administered with pure gold ionized water (2 ppm and 5 ppm), the tumor (arrow in the figure) is small compared to the control (0 ppm), in other words, the enlargement of the tumor is remarkable. Suppressed. In addition, the higher the concentration of pure gold ion water (that is, the smaller the 5 ppm group than the 2 ppm group), the smaller the tumor.
図２は、Jyg B-cell皮下移植３週目の腫瘍体積を示すグラフである。グラフに示すように、純金イオン水（２ｐｐｍおよび５ｐｐｍ）の投与群では、コントロール（０ｐｐｍ）と比較して腫瘍体積（Tumor volume）が有意に小さかった。なお、グラフ値は平均値（ｎ＝５）であり、「＊」は０ｐｐｍ群と比べ有意差があることを示す。＊Ｐ＜0.001（Student-t） FIG. 2 is a graph showing the tumor volume at 3 weeks after Jyg B-cell subcutaneous implantation. As shown in the graph, in the administration group of pure gold ionized water (2 ppm and 5 ppm), the tumor volume (Tumor volume) was significantly smaller than the control (0 ppm). In addition, a graph value is an average value (n = 5), "*" shows that there exists a significant difference compared with a 0 ppm group. * P <0.001 (Student-t)
また、図２のグラフに示すように、純金イオン水の濃度が高いほど（つまり、２ｐｐｍ投与群よりも５ｐｐｍ投与群のほうが）腫瘍体積は小さかった。 Further, as shown in the graph of FIG. 2, the tumor volume was smaller as the concentration of pure gold ion water was higher (that is, in the 5 ppm administration group than in the 2 ppm administration group).
以上の結果から、純金イオン水を経口投与することにより、乳癌細胞Jyg B-cellを皮下移植したヌードマウス体内での抗腫瘍増殖性効果が認められた。また、この効果は、純金イオン水の濃度が高いほど強く認められた。 From the above results, an antitumor proliferative effect was observed in nude mice transplanted subcutaneously with breast cancer cells Jyg B-cell by orally administering pure gold ionized water. This effect was recognized more strongly as the concentration of pure gold ion water was higher.
［実施例２］
本実施例においては、５種類の腫瘍細胞を使用して、本発明の金イオン含有液剤の抗腫瘍活性を評価した。使用した５種類の腫瘍細胞は、ヒト乳癌細胞株３種類（ＭＤＡ−ＭＢ，ＭＣＦ−７，ＯＣＵＢ−Ｆ）と、イヌ乳腺腫瘍細胞株２種類（ＣＦ，ＭＣＭ）である。
[Example 2]
In this example, the antitumor activity of the gold ion-containing solution of the present invention was evaluated using 5 types of tumor cells. The five types of tumor cells used were three types of human breast cancer cell lines (MDA-MB, MCF-7, OCUB-F) and two types of canine mammary tumor cell lines (CF, MCM).
実験方法は実施例１と同様であり、まず、金イオン濃度０ｐｐｍ、２．５ｐｐｍ、５ｐｐｍの水をそれぞれ５匹のヌードマウスに自由飲水させた。１週間後、各ヌードマウスに対して腫瘍細胞（106個）を頚部皮下に移植した。その後も継続的に純金イオン水（対照マウスには金イオンを含まない水）を自由飲水させ、移植３週間目にマウスを安楽死し、各マウスの腫瘍体積を測定した。これらの実験を上記５種の腫瘍細胞ごとに行い、得られた結果を統計処理し、０ｐｐｍの値との有意差を検定（Student-t）した。 The experimental method was the same as in Example 1. First, five nude mice were allowed to freely drink water with gold ion concentrations of 0 ppm, 2.5 ppm, and 5 ppm, respectively. One week later, tumor cells (10 6 cells) were transplanted subcutaneously into the neck of each nude mouse. Thereafter, pure gold ionized water (water that does not contain gold ions in control mice) was continuously allowed to drink freely, the mice were euthanized 3 weeks after transplantation, and the tumor volume of each mouse was measured. These experiments were performed for each of the above five types of tumor cells, and the obtained results were statistically processed, and a significant difference from the value of 0 ppm was tested (Student-t).
上記実験結果が、図３に示される。図３中、（ａ）〜（ｃ）のグラフに示すように、ヒト乳癌細胞（ＯＣＵＢ−Ｆ，ＭＤＡ−ＭＢ，ＭＣＦ−７）を移植した場合では、濃度５ｐｐｍの純金イオン水を自由飲水させたマウスにおいて有意に腫瘍の増殖が抑えられた。また、同図（ｄ）・（ｅ）のグラフに示すように、イヌ乳腺腫瘍細胞株２種類（ＣＦ，ＭＣＭ）を移植した場合では、濃度２．５ｐｐｍ、及び濃度５ｐｐｍの純金イオン水を自由飲水させたマウスにおいて有意に腫瘍の増殖が抑えられた。 The experimental results are shown in FIG. As shown in the graphs (a) to (c) of FIG. 3, when human breast cancer cells (OCUB-F, MDA-MB, MCF-7) were transplanted, pure gold ionized water with a concentration of 5 ppm was allowed to freely drink. Tumor growth was significantly suppressed in mice. In addition, as shown in the graphs (d) and (e) of the figure, when 2 types of canine mammary tumor cell lines (CF, MCM) were transplanted, pure gold ionized water with a concentration of 2.5 ppm and a concentration of 5 ppm was freely used. Tumor growth was significantly suppressed in the ingested mice.
以上のように、本発明のがん予防・治療用液剤および抗がん剤は、金イオンを有効成分として含有し、抗がん作用を有することから、医薬品および飲食品（特に健康飲料水）、さらには化粧品等への利用が可能である。 As described above, since the liquid for cancer prevention and treatment and the anticancer agent of the present invention contain gold ions as an active ingredient and have an anticancer action, pharmaceuticals and foods and drinks (especially health drinks) Furthermore, it can be used for cosmetics and the like.
Claims (4)
An anticancer agent containing gold ions as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005067639A JP2005314368A (en) | 2004-03-31 | 2005-03-10 | Gold ion-containing liquid medicine for preventing/treating cancer |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004107083 | 2004-03-31 | ||
| JP2005067639A JP2005314368A (en) | 2004-03-31 | 2005-03-10 | Gold ion-containing liquid medicine for preventing/treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2005314368A true JP2005314368A (en) | 2005-11-10 |
Family
ID=35442154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005067639A Pending JP2005314368A (en) | 2004-03-31 | 2005-03-10 | Gold ion-containing liquid medicine for preventing/treating cancer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2005314368A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11262377A (en) * | 1996-09-11 | 1999-09-28 | Japan Ace:Kk | Pure gold ion refreshing beverage |
| WO2002068342A1 (en) * | 2001-02-27 | 2002-09-06 | Phild Co., Ltd. | Method and device for manufacturing advanced water containing ultra-fine gold particles |
| JP2003104898A (en) * | 2001-07-26 | 2003-04-09 | Yoshio Murai | Gold ion-containing liquid preparation and method for manufacturing the same |
-
2005
- 2005-03-10 JP JP2005067639A patent/JP2005314368A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11262377A (en) * | 1996-09-11 | 1999-09-28 | Japan Ace:Kk | Pure gold ion refreshing beverage |
| WO2002068342A1 (en) * | 2001-02-27 | 2002-09-06 | Phild Co., Ltd. | Method and device for manufacturing advanced water containing ultra-fine gold particles |
| JP2003104898A (en) * | 2001-07-26 | 2003-04-09 | Yoshio Murai | Gold ion-containing liquid preparation and method for manufacturing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akhtar et al. | Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers | |
| Xu et al. | Hollow calcium/copper bimetallic amplifier for cuproptosis/paraptosis/apoptosis cancer therapy via cascade reinforcement of endoplasmic reticulum stress and mitochondrial dysfunction | |
| Tian et al. | An intelligent cupreous nanoplatform with self-supplied H2O2 and Cu2+/Cu+ conversion to boost cuproptosis and chemodynamic combined therapy | |
| Huber et al. | Nicotinamide: an update and review of safety & differences from niacin | |
| US10463690B2 (en) | Method and compositions for treating cancerous tumors | |
| KR20180004202A (en) | Topical and oral preparations containing taurine and magnesium to prevent and treat acne | |
| CN1492758A (en) | Method and formulation for antitumor and anti-metastatic effects | |
| AU2016259438A1 (en) | Mitigation of animal and plant diseases using bioavailable minerals | |
| US20070218126A1 (en) | Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis | |
| HK1049962A1 (en) | Method and formula for tumor remission and suppression of cancer | |
| JP2005314368A (en) | Gold ion-containing liquid medicine for preventing/treating cancer | |
| JP2003510363A (en) | Pharmaceutical composition and use thereof | |
| Choudhary et al. | Chronopharmacokinetics | |
| EP2694056B1 (en) | Therapeutic treatment | |
| EP4335442A1 (en) | Use of adenosine diphosphate ribose as adjuvant therapy for radiation and/or anticancer therapy | |
| Hong et al. | Efficient on-demand cuproptosis induction against triple-negative breast cancer via dual-responsive black phosphorus nanosheet | |
| PL225149B1 (en) | Water-soluble, stable complexes of gold (III), a method for preparing hydrogen-soluble, stable complexes of gold (III) and their use | |
| JP2007508331A (en) | Pharmaceutical composition comprising oxoplatin, its salts and derivatives | |
| US12357669B1 (en) | Modification of natural compounds to create products with enhanced health benefits | |
| US20220226371A1 (en) | Synthetic Cellular Membrane Chemical Ionophore Delivery System Comprising Hexa-Aqua Ligand Compositions | |
| Wang et al. | A cardiac-targeted nanozyme ameliorates myocardial infarction via antioxidation and regulation of MAPK signaling pathway | |
| PL235135B1 (en) | Water-soluble intelligent gold complexes (III), method for producing water-soluble intelligent gold complexes (III) and their application | |
| AU2022291691A1 (en) | Synthetic cellular membrane chemical ionophore delivery system comprising hexa-aqua ligand compositions | |
| WO2011119126A1 (en) | Use of oxalic acid in the production of a therapeutic preparation with anti-tumour activity in relation to malignant cells, a therapeutic preparation based thereon and a method of treatment | |
| PL232677B1 (en) | Water-soluble intelligent gold complexes (III) and application of water-soluble, intelligent gold complexes (III) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080125 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080307 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080321 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080307 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110607 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111108 |